ORIGINS AND HISTORY
The Centre for Medicines Research (CMR) was created in 1981 as a division of the Association of the British Pharmaceutical Industry (ABPI).
CMR’s initial role was to challenge public policy and regulatory issues that could adversely affect drug development. Early success, for example in amending long-term study requirements, placed CMR at the centre of pharmaceutical analysis and reform.
CMR’s greatest early success was in steering regulatory change. By carefully monitoring regulatory review times throughout the world, and facilitating international collaboration forums for industry, regulatory authorities and academia, we helped to reform and harmonize regulatory guidelines throughout US, Europe and Japan.
In the 1990s, in partnership with the world’s leading Pharmaceutical R&D organizations, CMR pioneered the development of reliable approaches to benchmarking pharmaceutical R&D.
In 2002, CMR International became a fully-independent, private company that was acquired by Thomson Reuters in 2006.
In parallel, we continue to support and develop the independent, not-for-profit CMR International Institute for Regulatory Science. The Institute continues to provide thought leadership in the development and implementation of regulatory policy.